NCT06891352 Optimization of Chrononutrition to Reduce the Risk of Disease in Shift Workers
| NCT ID | NCT06891352 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Salk Institute for Biological Studies |
| Condition | Night Shift Work |
| Study Type | INTERVENTIONAL |
| Enrollment | 180 participants |
| Start Date | 2025-06-02 |
| Primary Completion | 2028-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 180 participants in total. It began in 2025-06-02 with a primary completion date of 2028-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this randomized controlled trial, the investigators will assess the health impacts of optimizing the timing of dietary consumption in nurses and nursing assistants who work night shifts, have a habitual eating window of 14 hours or more, and elevated weight. Participants will be randomized to one of three groups: (1) dietary monitoring, (2) dietary monitoring plus 10-hour daytime time-restricted eating (TRE), or (3) TRE with a low-glycemic snack during night shifts. The study includes a 2-week screening/baseline health assessment, with follow-up health assessments at 3-, 6- (primary outcome), and 12 months.
Eligibility Criteria
Inclusion Criteria: * Age: 18-70 years * BMI ≥ 25 kg/m2 (or ≥ 23 kg/m2 for Asian adults) * Own a smartphone (Apple iOS or Android OS) * Baseline eating window ≥ 14 h/day * Night shift nurses and nursing assistants who are working a 12-hour night shift at least 3 days/week. * Have been doing night shift work for at least 3 months. * Patients on cardiovascular medications (HMG CoA reductase inhibitors (statins), metformin, lipid-modifying drugs (including over-the-counter drugs such as red yeast rice and fish oil), anti-hypertensive, drugs), are allowed * If patients have Type 2 Diabetes, they will be included in the study if A1c is less than 9 and they are not on insulin. Exclusion Criteria: * Insufficient dietary logging on the mCC app is defined as less than 7 of 14 days of baseline of dietary logging with a minimum of 2 items a day, at least 5 hours apart. * Type 1 Diabetes or Insulin-dependent Type 2 Diabetes. * Use of sulfonylurea or insulin within the last 3 months (due to unknown safety with TRE) * Use of medications that are known to cause weight loss such as SGLT2 inhibitors and GLP1 receptor agonists) * BMI \> 50 kg/m2 * Change in medications that could impact study outcomes within the past 3 months * Change in weight of \>4kg in the past 3 months * Women who are pregnant, breastfeeding, or are trying to become pregnant during the study period. If a participant becomes pregnant during the study, they will be excluded from continuing the study. * Systolic BP greater than 160 mmHg and/or diastolic BP greater than 110 mmHg at rest * Fasting LDL cholesterol greater than 250 mg/dL * Fasting triglycerides greater than 500g/dL * Active tobacco abuse or illicit drug use or history of treatment for alcohol abuse in the past 5 years. * Frequent (more than 4) travel involving a time zone change of more than 3 hours over the 1-year study period * Prolonged leave from work (a continuous month or longer) during the study * Active treatment for inflammatory and/or rheumatologic disease * History of a major adverse cardiovascular event within the past year (acute coronary syndrome, percutaneous coronary intervention, coronary artery bypass graft surgery, hospitalization for congestive heart failure, stroke/transient ischemic attack) * Uncontrolled arrhythmia (i.e. rate-controlled atrial fibrillation/atrial flutter are acceptable) * History of thyroid disease requiring dose titration of thyroid replacement medication(s) within the past 3 months (hypothyroidism on a stable dose of thyroid replacement therapy is allowed). * History of adrenal disease in the past 5 years * History of malignancy undergoing active treatment, except non-melanoma skin cancer, in the past 5 years * History of an eating disorder in the past 5 years * History of cirrhosis in the past 5 years * History of stage 4 or 5 chronic kidney disease or dialysis in the past 5 years * History of HIV/AIDs * Currently enrolled in weight-loss or weight-management program * History of surgical intervention for weight management within the past 2 years, or longer if deemed unsafe following review by medical investigators * Uncontrolled psychiatric disorder including prior hospitalization
Contact & Investigator
Emily Manoogian, Ph.D.
PRINCIPAL INVESTIGATOR
Salk Institute for Biological Studies
Frequently Asked Questions
Who can join the NCT06891352 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Night Shift Work. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06891352 currently recruiting?
Yes, NCT06891352 is actively recruiting participants. Contact the research team at research@mycircadianclock.org for enrollment information.
Where is the NCT06891352 trial being conducted?
This trial is being conducted at La Jolla, United States.
Who is sponsoring the NCT06891352 clinical trial?
NCT06891352 is sponsored by Salk Institute for Biological Studies. The principal investigator is Emily Manoogian, Ph.D. at Salk Institute for Biological Studies. The trial plans to enroll 180 participants.